依达拉奉右莰醇治疗大动脉粥样硬化性脑梗死的临床疗效及对血清炎性因子水平的影响

Clinical efficacy of edaravone dexborneol in the treatment of large artery atherosclerotic cerebral infarction and its influence on serum inflammatory factor levels

目的探讨依达拉奉右莰醇治疗大动脉粥样硬化性脑梗死的临床疗效及对血清炎性因子水平的影响。方法100例大动脉粥样硬化性脑梗死患者,采用随机数字表法分为实验组和对照组,每组50例。对照组采用基础治疗,实验组在对照组基础上加用依达拉奉右莰醇治疗。比较两组临床疗效,不良反应发生情况,治疗前后临床相关评分[美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)、日常生活能力量表(ADL)评分]及血清炎性因子指标[白细胞介素-6(IL-6)、C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)]水平。结果实验组治疗总有效率96%高于对照组的74%,差异有统计学意义(P<0.05)。两组治疗过程中均未发生不良反应。治疗7 d后,实验组NIHSS、mRS、ADL评分分别为(3.22±2.34)、(1.24±1.04)、(70.05±5.94)分,对照组NIHSS、mRS、ADL评分分别为(4.01±0.82)、(1.69±1.02)、(65.60±5.94)分。治疗90 d后,实验组NIHSS、mRS、ADL评分分别为(2.08±2.00)、(1.08±1.03)、(86.13±5.71)分,对照组NIHSS、mRS、ADL评分分别为(3.88±0.74)、(1.58±1.11)、(70.09±5.84)分。治疗7、90 d后,两组NIHSS、mRS评分低于本组治疗前,ADL评分高于本组治疗前,且实验组NIHSS、m RS评分低于对照组,ADL评分高于对照组,差异均有统计学意义(P<0.05)。治疗7 d后,两组IL-6、TNF-α、CRP水平均低于本组治疗前,且实验组IL-6(3.32±0.47)pg/ml、TNF-α(6.49±0.43)pg/ml、CRP(4.06±0.88)mg/L低于对照组的(5.11±1.03)pg/ml、(7.72±0.64)pg/ml、(4.46±0.97)mg/L,差异均有统计学意义(P<0.05)。结论依达拉奉右莰醇治疗大动脉粥样硬化性脑梗死的效果确切,可有效改善患者神经功能,减轻炎症反应,提高患者生活质量,且安全性良好。

Objective To discuss the clinical efficacy of edaravone dexborneol in the treatment of large artery atherosclerotic cerebral infarction and its influence on serum inflammatory factor levels.Methods A total of 100 patients with large artery atherosclerotic cerebral infarction were divided into experimental group and control group according to the random numerical table,with 50 cases in each group.The control group was treated with basic treatment,and the experimental group was treated with edaravone dexborneol on the basis of the control group.Both groups were compared in terms of clinical efficacy,occurrence of adverse reactions,levels of clinically relevant scores[National Institutes of Health Stroke Scale(NIHSS)score,modified Rankin Scale(mRS)score,Activities of Daily Living Scale(ADL)score]and serum inflammatory factor indicators[interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)]before and after treatment.Results The total effective rate of 96%in the experimental group was higher than that of 74%in the control group,and the difference was statistically significant(P<0.05).No adverse reactions occurred in both groups during treatment.After 7 d of treatment,the scores of NIHSS,mRS and ADL in the experimental group were(3.22±2.34),(1.24±1.04)and(70.05±5.94)points,and the scores of NIHSS,mRS and ADL in the control group were(4.01±0.82),(1.69±1.02)and(65.60±5.94)points.After 90 d of treatment,the scores of NIHSS,mRS and ADL in the experimental group were(2.08±2.00),(1.08±1.03)and(86.13±5.71)points,and the scores of NIHSS,mRS and ADL in the control group were(3.88±0.74),(1.58±1.11)and(70.09±5.84)points.After 7 and 90 d of treatment,the scores of NIHSS and mRS in both groups were lower than those before treatment in this group,and the score of ADL was higher than that before treatment in this group;the scores of NIHSS and mRS in the experimental group were lower than those in the control group;the score of ADL was higher than that in the control group;the differences were statistically significant(P<0.05).After 7 d of treatment,the levels of IL-6,TNF-αand CRP in both groups were lower than those before treatment in this group;the experimental group had IL-6 of(3.32±0.47)pg/ml,TNF-αof(6.49±0.43)pg/ml and CRP of(4.06±0.88)mg/L,which were lower than those of(5.11±1.03)pg/ml,(7.72±0.64)pg/ml and(4.46±0.97)mg/L in the control group;the differences were statistically significant(P<0.05).Conclusion The edaravone dexborneol has definite effect on large artery atherosclerotic cerebral infarction,which can effectively improve neurological function,reduce inflammation and improve quality of life of patients,and has high security.